Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 8/20 | 0.51 |
| ▸ | RBP4 | P02753 | 7/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NPY2R | P49146 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1763588 | 1.00 | SLC9A1 (0.51) | SLC9A1RBP4CYP2C19CYP2C9KCNH2 | |
| SCHEMBL1764112 | 1.00 | SLC9A1 (0.51) | SLC9A1RBP4CYP2C19CYP2C9KCNH2 | |
| SCHEMBL12593561 | 0.89 | MEN1 (0.39) | SLC9A1RBP4ESR1ESR2MEN1 | |
| SCHEMBL12593560 | 0.89 | MEN1 (0.39) | SLC9A1RBP4ESR1ESR2MEN1 | |
| SCHEMBL1763883 | 0.85 | SLC9A1 (0.69) | SLC9A1RBP4CYP2C19CYP2C9KCNH2 | |
| SCHEMBL1763494 | 0.84 | SLC9A1 (0.51) | SLC9A1RBP4CYP2C19CYP2C9KCNH2 | |
| SCHEMBL1763498 | 0.84 | SLC9A1 (0.51) | SLC9A1RBP4CYP2C19CYP2C9KCNH2 | |
| SCHEMBL1763399 | 0.82 | SLC9A1 (0.54) | SLC9A1RBP4CYP2C19CYP2C9CYP3A4 | |
| SCHEMBL1764148 | 0.82 | SLC9A1 (0.55) | SLC9A1RBP4CYP2C19CYP2C9MEN1 | |
| SCHEMBL1763461 | 0.82 | SLC9A1 (0.55) | SLC9A1RBP4CYP2C19CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118262-A1 | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118262-A1 | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors | NHERF1, SLC9A1, SLC9A5 | SLC9A1 2/4885RBP4 4521/4885CYP2C19 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.